

I hereby critify that this correspondence is being depositwith the United States Postal Service as first dass mell in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231,

on March 2, 2000

Betty J. Zea Name of Attome 36,069 Registration No.

Retty 7.

CP- 1444 4/15/00

Case 7247M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of

DOUGLAS J. DOBROZSI

Serial No. 09/361,542

: Group Art Unit 1615

Filed July 27, 1999

Examiner

For

ORAL LIQUID MUCOADHESIVE

COMPOSITIONS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

Pursuant to 37 CFR §§1.56, 1.97 and 1.98, record is being made below of a document which the Patent Office may wish to consider in connection with examination of the above-identified patent application. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 CFR §1.98(h) this Information Disclosure Statement does not constitute an admission of any kind and specifically is not an admission that the document listed on attached form PTO-1449 is, or is considered to be, material to the patentability of the above-identified patent application, as defined in 37 CFR §1.56(b).

Copies of the cited documents are attached. It is respectfully requested that the documents be carefully considered by the Examiner and made of record in the case.

Respectfully submitted,

DOUGLAS J. DOBROZSI

Ву

Betty J. Zea

Attorney for Applicants Registration No. 36,069

(513) 622-3952

Mach , 2000
The Procter & Gamble Company
Health Care Research Center (Box 1050)
PO Box 8006
Mason, OH 45040-8006
7247Misu.doc